Lymphoproliferation in children after liver transplantation

Journal of Pediatric Gastroenterology and Nutrition

Volumn 34, Issue 5, 2002, Pages 499-505

  Smets, Françoise ^a   Sokal, Etienne M ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; CYCLOPHOSPHAMIDE; EPSTEIN BARR VIRUS VACCINE; GAMMA INTERFERON; GANCICLOVIR; IMMUNOGLOBULIN; IMMUNOGLOBULIN M; INTERLEUKIN 6 ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RITUXIMAB; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY;

BONE MARROW TRANSPLANTATION; CELLULAR IMMUNITY; CLINICAL FEATURE; CYTOKINE RELEASE; EPSTEIN BARR VIRUS; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RATE; LIVER TRANSPLANTATION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; PATHOGENESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK FACTOR; SEROLOGY; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS SURVIVAL;

CHILD; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; INCIDENCE; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RISK FACTORS;

HUMAN HERPESVIRUS 4;

EID: 0036263096     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200205000-00004     Document Type: Review

References (63)

1. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: A growing concern
2. Early signs and risk factors for the increased incidence of Epstein-Barr virus-related posttransplant lymphoproliferative diseases in pediatric liver transplant recipients treated with tacrolimus
3. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders
4. The management of Epstein-Barr virus associated post-transplant lymphoproliferative disorders in pediatric solid-organ recipients
5. Epstein-Barr virus negative lymphoproliferative disorders in long-term survivors after heart, kidney, and liver transplant
6. De novo malignancies in pediatric organ transplant recipients
7. Epstein-Barr virus serology and Epstein-Barr virus-associated lymphoproliferative disorders in pediatric liver transplant recipients
8. Characteristics of Epstein-Barr virus primary infection in pediatric liver transplant recipients
9. Lymphoproliferative disorders after organ transplantation in children
10. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients
11. Posttransplant lymphoproliferative disorders in adult and pediatric renal transplant patients receiving tacrolimus-based immunosuppression
12. Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative disease
13. High levels of Epstein-Barr virus DNA in blood of solid-organ transplant recipients and their value in predicting posttransplant lymphoproliferative disorders
14. Patients at risk factor for development of post-transplant lymphoproliferative disorder: Plasma versus blood mononuclear cells as material for quantification of Epstein-Barr viral load using real-time quantitative polymerase chain reaction
15. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients
16. Epstein-Barr virus strategy in normal and neoplastic B cells
17. The biology of Epstein-Barr virus: Lessons learned from the virus and the host
18. Epstein-Barr virus latent infection in vivo
19. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
20. Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients
21. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy
22. Predictive value of Epstein-Barr virus genome copy number and BZLFI expression in blood lymphocytes of transplant recipients at risk for lymphoproliferative disease
23. BCL-6 gene mutations in posttransplant lymphoproliferative disorders predict response to therapy and clinical outcome
24. Indications and results of chemotherapy in children with posttransplant lymphoproliferative disease after liver transplantation
25. Characterization of Epstein-Barr virus-infected B cells in patients with posttransplantation lymphoproliferative disease: Disappearance after rituximab therapy does not predict clinical response
26. Effect of cyclosporine and tacrolimus on the growth of Epstein-Barr virus-transformed B-cell lines
27. A transformed view of cyclosporine
28. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease
29. Role of hepatitis C virus in lymphoproliferative disorders after liver transplantation
30. Posttransplantation lymphoproliferative disorder: Endoscopic findings
31. Acute tonsillitis as first manifestation of posttransplantation lymphoproliferative disorder (PTLD)
32. Post-transplant lymphoproliferative disorders: A working classification
33. Posttransplant lymphoproliferative disorder in liver allograft biopsies: A comparison of three methods for the demonstration of Epstein-Barr virus
34. The pathology of post-transplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression
35. Molecular genetic analysis of lymphoid tumors arising after organ transplantation
36. Posttransplantation lymphoproliferative disorders in solid organ recipients are predominantly aggressive tumors of host origin
37. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients
38. Serial measurement of Epstein-Barr viral load in peripheral blood in pediatric liver transplant recipients during treatment for posttransplant lymphoproliferative disease
39. Prospective longitudinal analysis of quantitative Epstein-Barr virus polymerase chain reaction in pediatric liver transplant recipients
40. Normalized quantification by real-time PCR of Epstein-Barr virus load in patients at risk for posttransplant lymphoproliferative disorders
41. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
42. EBNA1-specific CD4+ T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function
43. Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens
44. Rapid determination of Epstein-Barr virus-specific CD8+ T-cell frequencies by flow cytometry
45. A re-evaluation of the frequency of CD8+ T-cells specific for EBV in healthy virus carriers
46. Longitudinal dynamics of Epstein-Barr virus-specif ic cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder
47. Rapid reconstitution of Epstein-Barr virus specific T lymphocytes following allogeneic stem cell transplantation
48. Ratio between Epstein-Barr viral load and anti-EBV T-cells response as a predictive marker of posttransplant lymphoproliferative disease
49. Preventing acute rejection, Epstein-Barr virus infection, and posttransplant lymphoproliferative disorders after kidney transplantation: Use of acyclovir and mycophenolate mofetil in a steroid-free immunosuppressive protocol
50. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: A potential approach to prevention and treatment of posttransplant lymphoproliferative disorders
51. Rational management of posttransplant lymphoproliferative disorder in pediatric recipients
52. Management of post-transplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy
53. Effects of immunotherapy on experimental immunodeficiency-related lymphoproliferative disease
54. Treatment of Blymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: A multicenter phase 1-2 clinical trial
55. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation
56. Successful treatment of aggressive post transplant lymphoproliferative disorder using rituximab
57. Treatment of central nervous system B lymphoproliferative syndrome by local infusion of a B cell-specific monoclonal antibody
58. Reconstitution of EBV-specific T cell immunity in solid organ transplant recipients
59. Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease
60. Functional diversity of the CD8+ T-cell response to Epstein-Barr virus (EBV): Implications for the pathogenesis of EBV-associated lymphoproliferative disorders
61. Post-liver transplantation lymphoproliferative disorders with and without infusions of donor bone marrow cells
62. EBV structural antigens, gp350 and gp85, as targets for ex vivo virus-specific CTL during acute infectious mononucleosis: Potential use of gp350/gp85 CTL epitopes for vaccine design
63. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: Implications for vaccine development